Next-gen­er­a­tion se­quenc­ing: FDA of­fers guid­ance to stream­line path to mar­ket

The FDA on Thurs­day fi­nal­ized two guid­ance doc­u­ments re­lat­ed to next-gen­er­a­tion se­quenc­ing (NGS) and draft­ed new guid­ance on in­ves­ti­ga­tion­al in vit­ro di­ag­nos­tics (IVDs) in on­col­o­gy tri­als – all of which of­fer rec­om­men­da­tions to pro­vide test de­vel­op­ers with a more ef­fi­cient path to mar­ket.

The fi­nal­ized guid­ance doc­u­ments pro­vide NGS test de­vel­op­ers with rec­om­men­da­tions for de­sign­ing, de­vel­op­ing and val­i­dat­ing tests, as well as us­ing ge­net­ic vari­ant data­bas­es to sup­port clin­i­cal va­lid­i­ty.

Jef­frey Shuren

“The rapid adop­tion of NGS tech­nolo­gies in re­search and clin­i­cal set­tings is help­ing to iden­ti­fy count­less new ge­net­ic vari­ants. How­ev­er, in­for­ma­tion about ge­net­ic vari­ants is gen­er­al­ly stored in a man­ner that is not pub­licly ac­ces­si­ble,” ex­plained Jef­frey Shuren, di­rec­tor of FDA’s Cen­ter for De­vices and Ra­di­o­log­i­cal Health. “To­day’s re­lease of the FDA’s fi­nal guid­ance on ge­net­ic vari­ant data­bas­es will help change this par­a­digm by en­cour­ag­ing da­ta shar­ing and the ac­cu­mu­la­tion in pub­lic data­bas­es of ev­i­dence sup­port­ing the clin­i­cal va­lid­i­ty of ge­nom­ic tests to help pro­vide an even more ef­fi­cient path to mar­ket.”

The 7-page draft guid­ance, mean­while, de­scribes how spon­sors of cer­tain on­col­o­gy tri­als can use an op­tion­al stream­lined sub­mis­sion process to de­ter­mine whether use of an in­ves­ti­ga­tion­al IVD — in­clud­ing those that in­cor­po­rate NGS tech­nol­o­gy — in a tri­al of in­ves­ti­ga­tion­al can­cer drug or bi­o­log­i­cal prod­ucts is con­sid­ered sig­nif­i­cant risk, non­signif­i­cant risk or ex­empt from re­view.

Scott Got­tlieb

“This is a step to­ward our goal of hav­ing a com­mon fil­ing for a drug and di­ag­nos­tic sys­tem where the drug is co-de­vel­oped with a di­ag­nos­tic test,” FDA Com­mis­sion­er Scott Got­tlieb said in re­marks on Thurs­day.

Back­ground

NGS can en­able doc­tors to look across mil­lions of DNA changes that may de­ter­mine whether a per­son has or is at risk of de­vel­op­ing a ge­net­ic dis­ease, or to in­form treat­ment de­ci­sions, FDA ex­plained.

“The rapid adop­tion of NGS-based tests in both re­search and clin­i­cal prac­tice is lead­ing to iden­ti­fi­ca­tion of an in­creas­ing num­ber of ge­net­ic vari­ants (e.g., path­o­gen­ic, be­nign, and of un­known sig­nif­i­cance), in­clud­ing rare vari­ants that may be unique to a sin­gle in­di­vid­ual or fam­i­ly,” FDA said.

To date, FDA has au­tho­rized three NGS on­co-pan­els:

  • Foun­da­tionOne CDx, which was ap­proved in No­vem­ber 2017, and can de­tect ge­net­ic mu­ta­tions in 324 genes;
  • MSK-IM­PACT, al­so ap­proved in No­vem­ber 2017, which can de­tect ge­net­ic mu­ta­tions in 468 genes; and
  • On­comine Dx Tar­get Test, ap­proved in June 2017, which can de­tect ge­net­ic mu­ta­tions in 23 genes.

“Oth­er tests us­ing NGS tech­nol­o­gy au­tho­rized by FDA to date in­clude: Prax­is Ex­tend­ed RAS Pan­el (de­tects two genes) and Foun­da­tion­Fo­cus BR­CA (al­so de­tects two genes),” an FDA spokesper­son told Fo­cus.

“These pan­els can ac­cel­er­ate can­cer drug de­vel­op­ment and im­prove clin­i­cal out­comes by re­duc­ing pa­tient screen­ing time and costs. These tech­nolo­gies can help re­duce the risks as­so­ci­at­ed with the need for mul­ti­ple tis­sue biop­sies. And these plat­forms can be rapid­ly up­dat­ed to de­tect new onco­genes or gene vari­ants as these mark­ers are iden­ti­fied by re­searchers,” Got­tlieb ex­plained.

In 2017, FDA al­so took sev­er­al ac­tions to stream­line the de­vel­op­ment and re­view of a va­ri­ety of ge­net­ic-based tests – au­tho­riz­ing a third-par­ty op­tion for au­tho­riz­ing tu­mor pro­fil­ing tests, and out­lin­ing stan­dard­ized de­vel­op­ment cri­te­ria for con­sumer car­ri­er screen­ing tests to al­low for their mar­ket­ing with­out pri­or agency re­view. FDA al­so es­tab­lished such cri­te­ria for ge­net­ic health risk tests and pro­posed to al­low their mar­ket­ing af­ter a one-time agency re­view.

Fi­nal Guid­ance

One 41-page guid­ance fi­nal­ized Thurs­day, known as “Con­sid­er­a­tions for De­sign, De­vel­op­ment, and An­a­lyt­i­cal Val­i­da­tion of Next Gen­er­a­tion Se­quenc­ing (NGS)–Based In Vit­ro Di­ag­nos­tics (IVDs) In­tend­ed to Aid in the Di­ag­no­sis of Sus­pect­ed Germline Dis­eases,” pro­vides rec­om­men­da­tions for de­sign­ing, de­vel­op­ing and val­i­dat­ing NGS-based tests.

The guid­ance of­fers per­spec­tive on what the agency looks for in pre­mar­ket sub­mis­sions to de­ter­mine a test’s an­a­lyt­i­cal va­lid­i­ty, in­clud­ing how well the test de­tects the pres­ence or ab­sence of a ge­nom­ic change.

The oth­er 16-page guid­ance is­sued Thurs­day, ti­tled “Use of Pub­lic Hu­man Ge­net­ic Vari­ant Data­bas­es to Sup­port Clin­i­cal Va­lid­i­ty for Ge­net­ic and Ge­nom­ic-Based In Vit­ro Di­ag­nos­tics,” de­scribes how test de­vel­op­ers may re­ly on clin­i­cal ev­i­dence from FDA-rec­og­nized pub­lic data­bas­es to sup­port clin­i­cal claims.

The guid­ance de­scribes how prod­uct de­vel­op­ers can use these data­bas­es to sup­port the clin­i­cal val­i­da­tion of NGS tests that they are de­vel­op­ing. These pub­lic data­bas­es may in­clude re­sources like Clin­Gen, which is main­tained by the Na­tion­al In­sti­tutes of Health (NIH). Us­ing FDA-rec­og­nized data­bas­es will pro­vide test de­vel­op­ers with an ef­fi­cient path for mar­ket­ing clear­ance or ap­proval of a new test.

On 26 April, FDA will hold a we­bi­nar on the two fi­nal guid­ance doc­u­ments.


First pub­lished here. Reg­u­la­to­ry Fo­cus is the flag­ship on­line pub­li­ca­tion of the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety (RAPS), the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care and re­lat­ed prod­ucts, in­clud­ing med­ical de­vices, phar­ma­ceu­ti­cals, bi­o­log­ics and nu­tri­tion­al prod­ucts. Email news@raps.org for more in­for­ma­tion. 

Author

Zachary Brennan

managing editor, RAPS

Martin Shkreli [via Getty]

Pris­on­er #87850-053 does not get to add drug de­vel­op­er to his list of cred­its

Just days after Retrophin shed its last ties to founder Martin Shkreli, the biotech is reporting that the lead drug he co-invented flopped in a pivotal trial. Fosmetpantotenate flunked both the primary and key secondary endpoints in a placebo-controlled trial for a rare disease called pantothenate kinase-associated neurodegeneration, or PKAN.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

Hal Barron. GSK

GSK's Hal Bar­ron her­alds their sec­ond pos­i­tive PhI­II for cru­cial an­ti-BC­MA ther­a­py, point­ing to a push for quick OKs in a crowd­ed field

Hal Barron has his second positive round of Phase III data in hand for his anti-BCMA antibody drug conjugate belantamab mafodotin (GSK2857916). And GSK’s research chief says the data paves the way for their drive in search of an FDA approval for treating multiple myeloma. 

It’s hard to overestimate the importance of this drug for GSK, a cornerstone of Barron’s campaign to make a dramatic impact on the oncology market and provide some long-lost excitement for the pharma giant’s pipeline. They’re putting this BCMA program at the front of that charge — looking to lead a host of rivals all aimed at the same target.

UP­DAT­ED: An em­bold­ened As­traZeneca splurges $95M on a pri­or­i­ty re­view vouch­er. Where do they need the FDA to hus­tle up?

AstraZeneca is in a hurry.

We learned this morning that the pharma giant — not known as a big spender, until recently — forked over $95 million to get its hands on a priority review voucher from Sobi, otherwise known as Swedish Orphan Biovitrum.

That marks another step down on price for a PRV, which allows the holder to slash 4 months off of any FDA review time.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

We­bi­nar: Re­al World End­points — the brave new world com­ing in build­ing fran­chise ther­a­pies

Several biopharma companies have been working on expanding drug labels through the use of real world endpoints, combing through the data to find evidence of a drug’s efficacy for particular indications. But we’ve just begun. Real World Evidence is becoming an important part of every clinical development plan, in the soup-through-nuts approach used in building franchises.

I’ve recruited a panel of 3 top experts in the field — the first in a series of premium webinars — to look at the practical realities governing what can be done today, and where this is headed over the next few years, at the prodding of the FDA.

ZHEN SU — Merck Serono’s Senior Vice President and Global Head of Oncology
ELLIOTT LEVY — Amgen’s Senior Vice President of Global Development
CHRIS BOSHOFF — Pfizer Oncology’s Chief Development Officer

A premium subscription to Endpoints News is required to attend this webinar. Please upgrade to either an Insider or Enterprise plan for access. Already have Endpoints Premium? Please sign-in below. You can contact our Subscriptions team at help@endpointsnews.com with any issues.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Brian Kaspar. AveXis via Twitter

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

Brian Kaspar’s head was among the first to roll at Novartis after company execs became aware of the fact that manipulated data had been included in its application for Zolgensma, now the world’s most expensive therapy.

But in his first public response, the scientific founder at AveXis — acquired by Novartis for $8.7 billion — is firing back. And he says that not only was he not involved in any wrongdoing, he’s ready to defend his name as needed.

I reached out to Brian Kaspar after Novartis put out word that he and his brother Allen had been axed in mid-May, two months after the company became aware of the allegations related to manipulated data. His response came back through his attorneys.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

Bob Smith, Pfizer

Pfiz­er is mak­ing a $500M state­ment to­day: Here’s how you be­come a lead play­er in the boom­ing gene ther­a­py sec­tor

Three years ago, Pfizer anted up $150 million in cash to buy Bamboo Therapeutics in Chapel Hill, NC as it cautiously stuck a toe in the small gene therapy pool of research and development.

Company execs followed up a year later with a $100 million expansion of the manufacturing operations they picked up in that deal for the UNC spinout, which came with $495 million in milestones.

And now they’re really going for it.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

Video: Putting the AI in R&D — with Badhri Srini­vasan, Tony Wood, Rosana Kapeller, Hugo Ceule­mans, Saurabh Sa­ha and Shoibal Dat­ta

During BIO this year, I had a chance to moderate a panel among some of the top tech experts in biopharma on their real-world use of artificial intelligence in R&D. There’s been a lot said about the potential of AI, but I wanted to explore more about what some of the larger players are actually doing with this technology today, and how they see it advancing in the future. It was a fascinating exchange, which you can see here. The transcript has been edited for brevity and clarity. — John Carroll

Am­gen, Al­ler­gan biosim­i­lar of Roche's block­buster Rit­ux­an clears an­oth­er US piv­otal study 

Novartis $NVS may have given up, but Amgen $AMGN and Allergan $AGN are plowing ahead with their knockoff of Roche’s blockbuster biologic Rituxan in the United States.

Their copycat, ABP 798, was found to have a clinically equivalent impact as Rituxan — meeting the main goal of the study involving CD20-positive B-cell non-Hodgkin’s lymphoma patients. This is the second trial supporting the profile of the biosimilar. In January, it came through with positive PK results in patients with rheumatoid arthritis.

BeiGene and Mus­tang nail down spe­cial FDA sta­tus for top drugs; Roche bags added cov­er­age for Hem­li­bra

→ BeiGene $BGNE is getting a boost in its drive to field a rival to Imbruvica. The FDA has offered an accelerated review to zanubrutinib, a BTK inhibitor that has posted positive results for mantle cell lymphoma. The PDUFA date lands on February 27, 2020. The drug scored breakthrough status at the beginning of the year.

→ BeiGene isn’t the only biopharma company to gain special regulatory status today. Mustang Bio $MBIO and St. Jude Children’s Research Hospital announced that MB-107, a lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency, also known as bubble boy disease, has been granted Regenerative Medicine Advanced Therapy status.